12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 12 February 2025
Benralizumab for treating severe eosinophilic asthma (TA565)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 3 September 2019Published: 6 March 2019
Budesonide–glycopyrronium–formoterol fumarate for treating severe asthma in people 12 years and over TS ID 12018Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TS ID 10085]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating severe asthma with type 2 inflammation (TA751)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 December 2021
Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 August 2000
Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over (TA138)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 March 2008
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 November 2007
Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) (TA38)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 March 2002
Mepolizumab for treating severe eosinophilic asthma (TA671)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 February 2021
Omalizumab for treating severe persistent allergic asthma (TA278)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2013
Reslizumab for treating severe eosinophilic asthma (TA479)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 October 2017
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) (TA834)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 October 2022
Tezepelumab for treating severe asthma (TA880)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 April 2023